JP7462685B2 - 縦方向データを解釈して視覚化するための改善されたユーザインタフェースを有するシステムおよび方法 - Google Patents
縦方向データを解釈して視覚化するための改善されたユーザインタフェースを有するシステムおよび方法 Download PDFInfo
- Publication number
- JP7462685B2 JP7462685B2 JP2021573370A JP2021573370A JP7462685B2 JP 7462685 B2 JP7462685 B2 JP 7462685B2 JP 2021573370 A JP2021573370 A JP 2021573370A JP 2021573370 A JP2021573370 A JP 2021573370A JP 7462685 B2 JP7462685 B2 JP 7462685B2
- Authority
- JP
- Japan
- Prior art keywords
- genetic variants
- clinically relevant
- information
- computing device
- relevant information
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 99
- 230000001976 improved effect Effects 0.000 title description 12
- 230000002068 genetic effect Effects 0.000 claims description 310
- 238000011282 treatment Methods 0.000 claims description 120
- 230000015654 memory Effects 0.000 claims description 50
- 206010028980 Neoplasm Diseases 0.000 claims description 38
- 108700028369 Alleles Proteins 0.000 claims description 32
- 239000013610 patient sample Substances 0.000 claims description 23
- 230000003993 interaction Effects 0.000 description 126
- 108090000623 proteins and genes Proteins 0.000 description 108
- 201000010099 disease Diseases 0.000 description 99
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 99
- 230000001225 therapeutic effect Effects 0.000 description 75
- 238000012800 visualization Methods 0.000 description 62
- 238000012163 sequencing technique Methods 0.000 description 38
- 238000012545 processing Methods 0.000 description 37
- 238000001914 filtration Methods 0.000 description 34
- 239000003814 drug Substances 0.000 description 30
- 229940079593 drug Drugs 0.000 description 29
- 230000035772 mutation Effects 0.000 description 29
- 239000000523 sample Substances 0.000 description 26
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 24
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 24
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 23
- 238000012552 review Methods 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 19
- 102000054767 gene variant Human genes 0.000 description 16
- 150000007523 nucleic acids Chemical class 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 14
- 108020004707 nucleic acids Proteins 0.000 description 14
- 102000039446 nucleic acids Human genes 0.000 description 14
- 238000013079 data visualisation Methods 0.000 description 13
- 238000004590 computer program Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000004891 communication Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000000007 visual effect Effects 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 8
- 238000013442 quality metrics Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 238000013459 approach Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000002626 targeted therapy Methods 0.000 description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000007481 next generation sequencing Methods 0.000 description 5
- 230000002085 persistent effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010069754 Acquired gene mutation Diseases 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000007614 genetic variation Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000037439 somatic mutation Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 102000054766 genetic haplotypes Human genes 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 101150097381 Mtor gene Proteins 0.000 description 2
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 2
- 229960001686 afatinib Drugs 0.000 description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 108700021358 erbB-1 Genes Proteins 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229960003278 osimertinib Drugs 0.000 description 2
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 238000013515 script Methods 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000007482 whole exome sequencing Methods 0.000 description 2
- LIOLIMKSCNQPLV-UHFFFAOYSA-N 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2N=C1 LIOLIMKSCNQPLV-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108700040618 BRCA1 Genes Proteins 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229950005852 capmatinib Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002355 dual-layer Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 230000008826 genomic mutation Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B45/00—ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/30—Detection of binding sites or motifs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Data Mining & Analysis (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
Claims (20)
- 表示画面を備えるコンピューティング装置であって、
前記コンピューティング装置に通信可能に結合された1つ以上のメモリから第1のセットの遺伝子バリアントを取得し、前記第1のセットの遺伝子バリアントが、第1の時間に患者から取得された第1の患者サンプルに由来するシーケンスデータに由来するものであり、
前記コンピューティング装置に通信可能に結合された1つ以上のメモリから第2のセットの遺伝子バリアントを取得し、前記第2のセットの遺伝子バリアントが、第2の時間に患者から取得された第2の患者サンプルに由来するシーケンスデータに由来するものであり、
前記第1のセットの遺伝子バリアントおよび前記第2のセットの遺伝子バリアントの双方に関する、経時的な縦方向データを含む臨床的に関連する情報を前記表示画面上に表示し、ここで前記臨床的に関連する情報が、腫瘍純度情報を含む、ように構成される、コンピューティング装置。 - 前記臨床的に関連する情報が、腫瘍純度情報およびバリアント対立遺伝子頻度情報の双方を含む、請求項1に記載のコンピューティング装置。
- 前記バリアント対立遺伝子頻度情報が、数値的におよびグラフィカル表現の双方で提示される、請求項2に記載のコンピューティング装置。
- 前記グラフィカル表現が、バリアント対立遺伝子頻度のレベルと相関する高さを有する可変高さバーであり、前記可変高さバーが、時間と関連付けられる、請求項3に記載のコンピューティング装置。
- 前記可変高さバーが、腫瘍純度のレベルに相関する程度に着色されまたは陰影が付けられる、請求項4に記載のコンピューティング装置。
- 前記臨床的に関連する情報が、単一の棒グラフで提示される複数の可変高さバーを含む、請求項4に記載のコンピューティング装置。
- 前記グラフィカル表現が、バリアント対立遺伝子頻度のレベルと相関する程度まで充填される充填可能なオブジェクトであり、前記充填可能なオブジェクトが、時間と関連付けられる、請求項3に記載のコンピューティング装置。
- 前記充填可能なオブジェクトが、腫瘍純度のレベルに相関する色または陰影を使用して充填される、請求項7に記載のコンピューティング装置。
- 前記コンピューティング装置が、前記臨床的に関連する情報と共に患者処置情報を表示するようにさらに構成され、前記患者処置情報が、時間情報を含む、請求項1に記載のコンピューティング装置。
- 前記コンピューティング装置が、前記表示画面上の単一のパネルに前記臨床的に関連する情報を表示するようにさらに構成される、請求項1に記載のコンピューティング装置。
- 表示画面を有するコンピューティング装置に通信可能に結合された1つ以上のメモリから、前記コンピューティング装置のプロセッサによって第1のセットの遺伝子バリアントを取得することであって、前記第1のセットの遺伝子バリアントが、第1の時間に患者から取得された第1の患者サンプルに由来するシーケンスデータに由来するものである、第1のセットの遺伝子バリアントを取得することと、
前記コンピューティング装置に通信可能に結合された1つ以上のメモリから、前記プロセッサによって第2のセットの遺伝子バリアントを取得することであって、前記第2のセットの遺伝子バリアントが、第2の時間に患者から取得された第2の患者サンプルに由来するシーケンスデータに由来するものである、第2のセットの遺伝子バリアントを取得することと、
前記プロセッサによって、前記第1のセットの遺伝子バリアントおよび前記第2のセットの遺伝子バリアントの双方に関する、経時的な縦方向データを含む臨床的に関連する情報を前記表示画面上に表示することであって、前記臨床的に関連する情報が、腫瘍純度情報を含む、前記第1のセットの遺伝子バリアントおよび前記第2のセットの遺伝子バリアントの双方に関する臨床的に関連する情報を表示することと、を含む、方法。 - 前記臨床的に関連する情報が、腫瘍純度情報およびバリアント対立遺伝子頻度情報の双方を含む、請求項11に記載の方法。
- 前記バリアント対立遺伝子頻度情報が、数値的におよびグラフィカル表現の双方で提示される、請求項12に記載の方法。
- 前記グラフィカル表現が、バリアント対立遺伝子頻度のレベルと相関する高さを有する可変高さバーであり、前記可変高さバーが、時間と関連付けられる、請求項13に記載の方法。
- 前記可変高さバーが、腫瘍純度のレベルに相関する程度に着色されまたは陰影が付けられる、請求項14に記載の方法。
- 前記臨床的に関連する情報が、単一の棒グラフで提示される複数の可変高さバーを含む、請求項14に記載の方法。
- 前記グラフィカル表現が、バリアント対立遺伝子頻度のレベルと相関する程度まで充填される充填可能なオブジェクトであり、前記充填可能なオブジェクトが、時間と関連付けられる、請求項13に記載の方法。
- 前記プロセッサによって、腫瘍純度のレベルに相関する色または陰影を使用して充填可能なオブジェクトを充填することをさらに含む、請求項17に記載の方法。
- 前記プロセッサによって、前記臨床的に関連する情報と共に患者処置情報を表示することをさらに含み、前記患者処置情報が、時間情報を含む、請求項11に記載の方法。
- 前記プロセッサによって、前記表示画面上の単一のパネルに前記臨床的に関連する情報を表示することをさらに含む、請求項11に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962861018P | 2019-06-13 | 2019-06-13 | |
US62/861,018 | 2019-06-13 | ||
US201962925158P | 2019-10-23 | 2019-10-23 | |
US62/925,158 | 2019-10-23 | ||
PCT/EP2020/066248 WO2020249704A1 (en) | 2019-06-13 | 2020-06-12 | Systems and methods with improved user interface for interpreting and visualizing longitudinal data |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022535951A JP2022535951A (ja) | 2022-08-10 |
JP7462685B2 true JP7462685B2 (ja) | 2024-04-05 |
Family
ID=71105448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021573370A Active JP7462685B2 (ja) | 2019-06-13 | 2020-06-12 | 縦方向データを解釈して視覚化するための改善されたユーザインタフェースを有するシステムおよび方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220310208A1 (ja) |
EP (1) | EP3984037A1 (ja) |
JP (1) | JP7462685B2 (ja) |
CN (1) | CN113939881A (ja) |
WO (1) | WO2020249704A1 (ja) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016513303A (ja) | 2013-01-29 | 2016-05-12 | モレキュラー ヘルス ゲーエムベーハー | 臨床判断支援のためのシステムおよび方法 |
JP2017503258A (ja) | 2013-12-12 | 2017-01-26 | アビ−バイオティクス エス.エー. | 薬剤の使用に関する個人別推奨案をコンピュータの補助のもとでウエブ・ベースで提供する方法とシステムとコンピュータで読み取り可能な記憶媒体 |
WO2017172958A1 (en) | 2016-03-29 | 2017-10-05 | Regeneron Pharmaceuticals, Inc. | Genetic variant-phenotype analysis system and methods of use |
JP2017527050A5 (ja) | 2015-06-18 | 2018-07-26 | ||
JP2018533123A (ja) | 2015-09-10 | 2018-11-08 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 統合された臨床ケアのための情報科学プラットフォーム |
JP2022529276A (ja) | 2019-04-17 | 2022-06-20 | テンパス・ラボズ・インコーポレイテッド | コラボレーティブ人工知能の方法およびシステム |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130268290A1 (en) * | 2012-04-02 | 2013-10-10 | David Jackson | Systems and methods for disease knowledge modeling |
WO2015198074A1 (en) * | 2014-06-27 | 2015-12-30 | Illumina Cambridge Limited | Methods, applications and systems for processing and presenting gene sequencing information |
US10665328B2 (en) * | 2014-06-30 | 2020-05-26 | QIAGEN Redwood City, Inc. | Methods and systems for interpretation and reporting of sequence-based genetic tests |
CA2953942C (en) * | 2014-06-30 | 2023-10-03 | QIAGEN Redwood City, Inc. | Methods and systems for interpretation and reporting of sequence-based genetic tests |
SG11201805600VA (en) | 2016-01-15 | 2018-07-30 | Ventana Med Syst Inc | Deep sequencing profiling of tumors |
US20210222248A1 (en) | 2016-04-15 | 2021-07-22 | Roche Sequencing Solutions, Inc. | Detecting cancer driver genes and pathways |
EP3879535A1 (en) * | 2017-06-13 | 2021-09-15 | BostonGene Corporation | Systems and methods for identifying cancer treatments from normalized biomarker scores |
WO2020142551A1 (en) * | 2018-12-31 | 2020-07-09 | Tempus Labs | A method and process for predicting and analyzing patient cohort response, progression, and survival |
-
2020
- 2020-06-12 EP EP20733551.4A patent/EP3984037A1/en active Pending
- 2020-06-12 JP JP2021573370A patent/JP7462685B2/ja active Active
- 2020-06-12 WO PCT/EP2020/066248 patent/WO2020249704A1/en active Application Filing
- 2020-06-12 US US17/619,164 patent/US20220310208A1/en active Pending
- 2020-06-12 CN CN202080042740.5A patent/CN113939881A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016513303A (ja) | 2013-01-29 | 2016-05-12 | モレキュラー ヘルス ゲーエムベーハー | 臨床判断支援のためのシステムおよび方法 |
JP2017503258A (ja) | 2013-12-12 | 2017-01-26 | アビ−バイオティクス エス.エー. | 薬剤の使用に関する個人別推奨案をコンピュータの補助のもとでウエブ・ベースで提供する方法とシステムとコンピュータで読み取り可能な記憶媒体 |
JP2017527050A5 (ja) | 2015-06-18 | 2018-07-26 | ||
JP2018533123A (ja) | 2015-09-10 | 2018-11-08 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 統合された臨床ケアのための情報科学プラットフォーム |
WO2017172958A1 (en) | 2016-03-29 | 2017-10-05 | Regeneron Pharmaceuticals, Inc. | Genetic variant-phenotype analysis system and methods of use |
JP2022529276A (ja) | 2019-04-17 | 2022-06-20 | テンパス・ラボズ・インコーポレイテッド | コラボレーティブ人工知能の方法およびシステム |
Also Published As
Publication number | Publication date |
---|---|
CN113939881A (zh) | 2022-01-14 |
EP3984037A1 (en) | 2022-04-20 |
WO2020249704A1 (en) | 2020-12-17 |
JP2022535951A (ja) | 2022-08-10 |
US20220310208A1 (en) | 2022-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Loos | 15 years of genome-wide association studies and no signs of slowing down | |
Li et al. | VarCards: an integrated genetic and clinical database for coding variants in the human genome | |
US20190311784A1 (en) | Genome explorer system to process and present nucleotide variations in genome sequence data | |
US9619624B2 (en) | Systems and methods for identifying unknown drug targets via adverse event data | |
EP3864659A1 (en) | Multi-omic search engine for integrative analysis of cancer genomic and clinical data | |
US20220301672A1 (en) | Computing device with improved user interface for interpreting and visualizing data | |
US20170169163A1 (en) | Methods and systems for genome comparison | |
Munz et al. | Qtlizer: comprehensive QTL annotation of GWAS results | |
US20220319637A1 (en) | Precision medicine portal for human diseases | |
Mangan et al. | The UCSC genome browser: what every molecular biologist should know | |
GCCL Cardenas et al. | Mendel, MD: A user-friendly open-source web tool for analyzing WES and WGS in the diagnosis of patients with Mendelian disorders | |
JP7462685B2 (ja) | 縦方向データを解釈して視覚化するための改善されたユーザインタフェースを有するシステムおよび方法 | |
Gu et al. | ShinyCNV: a Shiny/R application to view and annotate DNA copy number variations | |
CA2800722A1 (en) | Systems and methods for multivariate analysis of adverse event data | |
Benet‐Pagès et al. | Variant interpretation: UCSC genome browser recommended track sets | |
US20240079094A1 (en) | Method and system for providing genetic information analysis results | |
EP2801047B1 (en) | Systems and methods for multivariate analysis of adverse event data | |
Pulvirenti et al. | OncoReport: a system for integrative NGS analysis in precision medicine | |
Ye et al. | WHATIF: an open-source desktop application for extraction and management of the incidental findings from next-generation sequencing variant data | |
KR102598073B1 (ko) | 유전 정보 분석 결과 제공 방법 및 시스템 | |
Bradshaw III et al. | Rapid, Reliable, and Interpretable CNV Curation Visualizations for Diagnostic Settings with SeeNV | |
Sabik et al. | A computational approach for identification of core modules from a co-expression network and GWAS data | |
장영준 | An integrated clinical and genomic information system for cancer precision medicine | |
Mulder et al. | EXtrACtor–A tool for multiple queries and data extractions from the EXAC and gnomAD database |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220127 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230403 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230703 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231013 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240208 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240214 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240305 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240326 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7462685 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |